In this study, the investigators plan to compare the incidence and complications of intraoperative floppy iris syndrome (IFIS) during cataract surgery in patients taking tamsulosin (Flomax) and treated with retrobulbar injection of anesthesia, versus injection of Healon 5 viscoelastic into the anterior chamber...
Date First Received: February 25, 2008
Last Updated: September 5, 2008
Verified by: Penn State University, January 2008
Clinical Trial Phase: N/A | Start Date: February 2008
Overall Status: Recruiting
Estimated Enrollment: 100
Brief Summary
Official Title: “Retrobulbar Injection of Anesthesia Versus Injection of Healon 5 Viscoelastic Into the Anterior Chamber in the Management of Intraoperative Floppy Iris Syndrome”
Condition Keyword(s):
Intervention(s):
In this study, the investigators plan to compare the incidence and complications of intraoperative floppy iris syndrome (IFIS) during cataract surgery in patients taking tamsulosin (Flomax) and treated with retrobulbar injection of anesthesia, versus injection of Healon 5 viscoelastic into the anterior chamber.
Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Study Primary Completion Date: May 2010
Intervention(s) in this Clinical Trial
- Procedure: Healon 5 injection
- Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
- Procedure: Retrobulbar anesthetic injection
- 3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
Arms, Groups and Cohorts in this Clinical Trial
- Active Comparator: 1
- Healon 5
- Experimental: 2
- Retrobulbar Anesthetic Injection
Outcome Measures for this Clinical Trial
Primary Measures
- Preoperative pupil diameter, pupil diameter after hydrodissection, pupil diameter after nuclear removal, pupil diameter after cortex removal, and pupil
diameter at conclusion of surgery.
- Time Frame: 2 years
Safety Issue?: No
- Time Frame: 2 years
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- All cataract patients taking tamsulosin
Exclusion Criteria:
- Patients with any history of iridocyclitis
- Presence of iris neovascularization
- History of prior iris surgery
- Presence of traumatic cataracts
- Presence of zonular dialysis
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Penn State University
Overall Clinical Trial Officials and Contacts
Ahmad A Aref, M.D. Principal Investigator The Penn State Hershey Eye Center
Overall Contact: Ahmad A Aref, M.D. (717) 531-8783 aaref@hmc.psu.edu
Related Publications
References
Chang DF, Osher RH, Wang L, Koch DD. Prospective multicenter evaluation of cataract surgery in patients taking tamsulosin (Flomax). Ophthalmology. 2007 May;114(5):957-64.
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00627913
Study ID Number: 27170
ClinicalTrials.gov Identifier: NCT00627913
Health Authority: United States: Institutional Review Board
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.